The expression of TRIP-Brs was significantly higher in basal, luminal-A/B clinical subtypes, enriched ER+, and grade1/2 as compared to ER in the Gene Expression-Based Outcome for Breast Cancer Online (GOBO) database (Figure 4B). Here, ESR1 is linked to breast carcinoma.